Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference
San Diego, California–(Newsfile Corp. – August 3, 2021) – Tryp Therapeutics (CNSX:TRYP.CN) (OTCQB:TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Conference. The conference will be held virtually on August 10-12, 2021. Greg McKee, […]
COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor conferences
COMPASS Pathways plc (Nasdaq:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in fireside chats at two investor conferences in August as follows: — BTIG Virtual Biotechnology Conference: 10:30am ET on 9 August — Canaccord Genuity 41 […]
HAVN Life Harvests First Crop of Psilocybin Mushrooms at its Jamaica Facility
HAVN Life will export to Delic Labs in Canada for quality control and testing. This makes HAVN Life the first in the Caribbean Community and Common Market to export psilocybin. VANCOUVER, BC / ACCESSWIRE / August 3, 2021 / HAVN Life Sciences Inc. (CNSX:HAVN.CN) (OTCPINK:HAVLF) (FSE:5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds […]
MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology
NEW YORK , Aug. 3, 2021 /PRNewswire/ — MindMed (NASDAQ:MNMD) (NEO:MMED) (DE:MMQ), a leading biotech company developing psychedelic-inspired therapies, announced today that it will participate in and financially support the Digital Medicine Society’s (DiMe) Digital Health Measurement Collaborative Community (DATAcc), an effort to develop best practices and streamline the medical field’s approaches to measuring health using digital technologies. […]
Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option
Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced overnight marketed offering (the “Offering”) including the exercise in full of the over-allotment option granted to the Underwriters (as defined herein). In connection with the Offering, the Company […]
